Free Trial

Lakeshore Capital Group Inc. Takes $534,000 Position in Merck & Co., Inc. (NYSE:MRK)

Merck & Co., Inc. logo with Medical background

Lakeshore Capital Group Inc. acquired a new stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 5,368 shares of the company's stock, valued at approximately $534,000.

Other large investors have also added to or reduced their stakes in the company. Midwest Capital Advisors LLC bought a new stake in Merck & Co., Inc. in the 4th quarter valued at $26,000. Financial Life Planners purchased a new stake in Merck & Co., Inc. in the fourth quarter worth about $28,000. Noble Wealth Management PBC purchased a new stake in shares of Merck & Co., Inc. during the fourth quarter worth about $28,000. Halbert Hargrove Global Advisors LLC purchased a new position in shares of Merck & Co., Inc. in the 4th quarter valued at approximately $28,000. Finally, Promus Capital LLC acquired a new position in Merck & Co., Inc. during the 4th quarter valued at approximately $30,000. Institutional investors own 76.07% of the company's stock.

Merck & Co., Inc. Price Performance

MRK stock traded down $1.42 during midday trading on Wednesday, reaching $76.17. The stock had a trading volume of 12,271,265 shares, compared to its average volume of 12,567,465. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $134.63. The company has a current ratio of 1.36, a quick ratio of 1.15 and a debt-to-equity ratio of 0.79. The company's fifty day simple moving average is $81.09 and its 200 day simple moving average is $91.05. The company has a market cap of $191.27 billion, a price-to-earnings ratio of 11.32, a price-to-earnings-growth ratio of 0.77 and a beta of 0.43.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported $2.22 earnings per share for the quarter, topping analysts' consensus estimates of $2.16 by $0.06. The firm had revenue of $15.53 billion for the quarter, compared to analyst estimates of $15.59 billion. Merck & Co., Inc. had a net margin of 26.67% and a return on equity of 45.35%. Merck & Co., Inc.'s quarterly revenue was down 1.6% on a year-over-year basis. During the same period in the previous year, the business posted $2.07 earnings per share. As a group, sell-side analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. announced that its board has initiated a share repurchase plan on Tuesday, January 28th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 4.1% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company's board believes its shares are undervalued.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 8th. Investors of record on Monday, June 16th will be given a dividend of $0.81 per share. The ex-dividend date is Monday, June 16th. This represents a $3.24 dividend on an annualized basis and a yield of 4.25%. Merck & Co., Inc.'s payout ratio is 47.16%.

Insider Buying and Selling

In related news, SVP Dalton E. Smart III sold 4,262 shares of the firm's stock in a transaction dated Friday, April 25th. The stock was sold at an average price of $82.76, for a total transaction of $352,723.12. Following the completion of the sale, the senior vice president now directly owns 7,778 shares of the company's stock, valued at approximately $643,707.28. This trade represents a 35.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.09% of the stock is currently owned by company insiders.

Analyst Ratings Changes

MRK has been the topic of several research reports. Morgan Stanley cut their target price on Merck & Co., Inc. from $113.00 to $106.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 5th. Deutsche Bank Aktiengesellschaft lowered shares of Merck & Co., Inc. from a "buy" rating to a "hold" rating and cut their price objective for the stock from $128.00 to $105.00 in a research note on Tuesday, February 18th. Bank of America decreased their target price on shares of Merck & Co., Inc. from $118.00 to $112.00 and set a "buy" rating for the company in a research report on Wednesday, February 5th. Cantor Fitzgerald lowered shares of Merck & Co., Inc. from an "overweight" rating to a "cautious" rating in a report on Tuesday, May 20th. Finally, Wall Street Zen lowered Merck & Co., Inc. from a "strong-buy" rating to a "buy" rating in a research note on Friday, April 25th. One analyst has rated the stock with a sell rating, twelve have issued a hold rating, seven have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $109.19.

Get Our Latest Research Report on Merck & Co., Inc.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

See Also

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Should You Invest $1,000 in Merck & Co., Inc. Right Now?

Before you consider Merck & Co., Inc., you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.

While Merck & Co., Inc. currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines